SANKYO/PARKE-DAVIS TROGLITAZONE POST-APPROVAL INTERACTION STUDIES URGED; NARROW, TYPE II DIABETES INDICATION WINS UNANIMOUS APPROVAL RECOMMENDATION
Executive Summary
Studies assessing the interaction of Sankyo/Parke-Davis' Rezulin (troglitazone) diabetes treatment with other drugs should be performed following approval, Committee Chairman Henry Bone, MD, Henry Ford Hospital (Detroit), said during FDA's Endocrinologic & Metabolic Drugs Advisory Committee meeting Dec. 11.